Dr. Herbst is a Professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.
Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.
Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.
After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.
Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians
Patient Care Organizations
Medical Oncology: Subset Medical Oncology Faculty
Medical Oncology AB of Internal Medicine (1997)
|Lung||TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)|
|Lung||A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE: Phase 1b/2 INvestigation of anti-Notch Antibody Therapy with Cisplatin and Etoposide in Small Cell Lung Carcinoma Safety and Efficacy)|
|Unknown Sites||An Investigation of Tumor-Derived Mutated DNA in the Blood and Urine as a Biomarker for Cancer Treatment Response|
|Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid||A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies|
|Lung||Lung Cancer Mutation Consortium Protocol|
|A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (S1206/NCI Study Number 8811)|
|Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach||A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS|
|Lung||A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer|
|Lung, Melanoma, skin||A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases|
|Lung||A Phase Ib Study of the Safety and Pharmacology of MPDL3280A administered with Erlotinib or Alectinib in Patients with Advanced Non-Small Cell Lung Cancer|
|Lung||A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)|
|Lung||A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)|
|Lung||A Phase III, Randomized, Open-label, Crossover, Multi-center, Safety and Efficacy Study to Evaluate NAB-PACLITAXEL (ABRAXANEÂ®) as Maintenance Treatment After Induction with NAB-PACLITAXEL plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)|
|Lung||A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer|
|Lung||S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer|
|Unknown Sites||Tumor Molecular Profiling|
|Lung||A Phase 2, Multicenter, Single-arm Study of Oral AP26113 in Patients with ALK-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Crizotinib|
|Melanoma, skin||A PHASE 1b STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS|
|Lung, Melanoma, skin||A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients with Metastatic Melanoma or NSCLC|
|Unknown Sites||Novel Treatment to Enhance Smoking Cessation before Cancer Surgery|